Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. Company
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo OpGen, Inc.
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

Number of employees : 110 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Molecular Diagnostics and Informatics2.1762%2.7064.2% +24.73%
Collaboration1.3337.9%1.3431.9% +1.31%
Laboratory0.0050.2%0.1684% +2986.22%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States3.50100%4.21100% +20.46%
Managers
NameAgeSinceTitle
Oliver Schacht, Dr.492020Chief Executive Officer & Director
Timothy C. Dec612015CFO, Secretary & Chief Accounting Officer
Vadim Sapiro492011Chief Information Officer
G. Terrance Walker, Dr.602013Senior Vice President-Research & Development
Faranak Atrzadeh--Chief Marketing & Scientific Affairs Officer
Johannes Bacher512020Chief Operating Officer
R. Donald Elsey662019Independent Director
Mario P. Crovetto662020Independent Director
Prabhavathi B. Fernandes, Dr.712020Independent Director
Bill E. Rhodes662020Non-Executive Chairman
Members of the board
NameAgeSinceTitle
Bill E. Rhodes662020Non-Executive Chairman
R. Donald Elsey662019Independent Director
Mario P. Crovetto662020Independent Director
Prabhavathi B. Fernandes, Dr.712020Independent Director
Oliver Schacht, Dr.492020Chief Executive Officer & Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,266,482 38,183,956 99.8% 0 0.0% 99.8%
Shareholders
NameEquities%
The Vanguard Group, Inc. 1,282,370 3.35%
Heights Capital Management, Inc. 200,000 0.52%
Geode Capital Management LLC 195,024 0.51%
Aviva Investors Global Services Ltd. 187,737 0.49%
G1 Execution Services LLC 75,256 0.20%
Citadel Advisors LLC 73,277 0.19%
National Asset Management, Inc. 59,630 0.16%
BlackRock Fund Advisors 54,939 0.14%
Bank of America, NA (Private Banking) 48,407 0.13%
Bayesian Capital Management LP 47,900 0.13%
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
OPGEN, INC.13.73%89
MODERNA, INC.89.37%79 438
LONZA GROUP AG17.02%54 990
IQVIA HOLDINGS INC.36.31%46 809
CELLTRION, INC.-24.37%33 149
SEAGEN INC.-13.60%27 461
HANGZHOU TIGERMED CONSULTING CO., LTD10.14%23 290
PHARMARON BEIJING CO., LTD.55.10%22 324
CUREVAC N.V.16.92%21 497
ALNYLAM PHARMACEUTICALS, INC.29.49%19 783
INCYTE CORPORATION-4.85%18 280
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.41.82%17 735
BIO-TECHNE CORPORATION39.36%17 211
PPD, INC.35.45%16 278
NOVAVAX, INC.58.05%13 054
ICON PUBLIC LIMITED COMPANY7.99%11 130
QIAGEN N.V.-9.12%10 970
PRA HEALTH SCIENCES, INC.32.68%10 785
CRISPR THERAPEUTICS AG-19.07%9 928
SYNEOS HEALTH, INC.24.48%8 763
GENSCRIPT BIOTECH CORPORATION181.03%8 473